par Rosiere, Rémi 
;Hureaux, José;Levet, Vincent ;Amighi, Karim ;Wauthoz, Nathalie
Référence Revue des maladies respiratoires, 35, 4, page (378-389)
Publication Publié, 2018-05
;Hureaux, José;Levet, Vincent ;Amighi, Karim ;Wauthoz, Nathalie Référence Revue des maladies respiratoires, 35, 4, page (378-389)
Publication Publié, 2018-05
Article révisé par les pairs
| Résumé : | Lung tumours have a high incidence and cause many deaths worldwide. Despite progresses in treatment with targeted therapies and immunotherapies, the global 5-year survival rate remains low. In this context, inhaled chemotherapy could provide a means to intensify current therapeutic modalities. This review is based on clinical studies of inhaled chemotherapy against lung tumours. The advantages of this approach in terms of pharmacokinetic ratio and therapeutic index are presented as well as the limitations including contraindications and pulmonary side effects. Moreover, the challenges linked to technical aspects around administration are identified (inhalation device and facilities to limit aerosol propagation and exposure of healthcare professionals). The current developments proposed to overcome these challenges are described briefly. Also discussed are the potential applications for the distribution of the inhaled anticancer drug into tumour-bearing respiratory tracts and finally the potential indications for current therapeutic modalities. |
